TriangleNCT00084747 · REGISTRY CONDITION SEARCH
Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE1, PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2020-08-17
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Giving bortezomib as maintenance therapy after autologous stem cell transplantation may kill more cancer cells and prolong remission. PURPOSE: This phase I/II trial is studying the side effects and best dose of adjuvant bortezomib as maintenance therapy and to see how well it works in treating patients who have undergone stem cell transplantation for intermediate or advanced multiple myeloma.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Diagnosis of intermediate or advanced multiple myeloma meeting criteria for at least 1 2 following: * Intermediate- to high-M-component production rates (immunoglobulin \[Ig\]G \> 5 g/dL or immunoglobulin A (IgA) \> 3 g/dL or urine M component \> 4 g/24 hours) * More than one osteolytic bone lesion or radiographic evidence of diffuse osteoporosis * β-2 microglobulin \> 3 * Nonsecretory myeloma if bone marrow plasmacytosis is greater than 30% * Must have undergone autologous peripheral blood stem cell transplantation within the past 3-4 months * Age 18 to 69 years old * Absolute neutrophil count ≥ 1,000/mm\^3 * Platelet count ≥ 30,000/mm\^3 * serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) ≤ 300 IU * Bilirubin ≤ 2 mg/dL * Creatinine ≤ 2.0 mg/dL * Creatinine clearance ≥ 30 mL/min * Negative pregnancy test * Fertile patients must use effective contraception Exclusion Criteria: * concurrent major cardiac disease that would preclude study participation * concurrent major pulmonary disease that would preclude study participation * pregnant or nursing * peripheral neuropathy ≥ grade 2 * history of hypersensitivity to bortezomib, boron, or mannitol * concurrent major gastrointestinal or bladder disease that would preclude study participation * concurrent major neurologic or psychiatric disease that would preclude study participation * dementia or significantly altered mental status that would preclude giving informed consent * prior interferon post-transplantation * prior thalidomide post-transplantation * prior chemotherapy post-transplantation * prior radiotherapy post-transplantation * prior investigational therapy post-transplantation * prior bortezomib * prior therapy for myeloma post-transplantation * other concurrent anti-myeloma therapy * other concurrent investigational therapy
- healthy Volunteers
- false
- maximum Age
- 69 Years
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- intervention Names
- Drug: bortezomib
- label
- bortezomib
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- bortezomib
- name
- bortezomib
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 30
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Disease Progression: The day when bone marrow recurrence and/or new lytic bone marrow lesions on radiograph and/or progressive M-component paraprotein (\~ 25% increase) were detected. Paraprotein progression will be confirmed labs on the consecutive month.
- measure
- Progression-free Survival
- time Frame
- signed consent to progression or end of trial. Up to 5 years.
- secondary Outcomes
- measure
- Overall Survival
- time Frame
- up to 5 years from time of consent
Full study description
- brief Summary
- RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Giving bortezomib as maintenance therapy after autologous stem cell transplantation may kill more cancer cells and prolong remission. PURPOSE: This phase I/II trial is studying the side effects and best dose of adjuvant bortezomib as maintenance therapy and to see how well it works in treating patients who have undergone stem cell transplantation for intermediate or advanced multiple myeloma.
- detailed Description
- OBJECTIVES: * Determine response rate, as defined by resolution of bone marrow plasmacytosis and monoclonal paraproteinemia, in the first year after autologous peripheral blood stem cell transplantation in patients with intermediate or advanced multiple myeloma treated with adjuvant bortezomib. * Compare progression-free survival of patients treated with adjuvant bortezomib with historical controls treated with autologous transplantation alone. * Determine the toxicity of this drug in these patients (phase I). OUTLINE: This is a multicenter, dose-escalation study. Patients receive bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 3-30 patients will be accrued for this study within 2 years.
Source references
- references
- citation
- Schiller GJ, Sohn JP, Malone P, et al.: Phase I/II trial of bortezomib maintenance following autologous peripheral blood progenitor cell transplantation as treatment for intermediate- and advanced-stage multiple myeloma. [Abstract] Biol Blood Marrow Transplant 13 (2 Suppl 1): A-153, 57, 2007.
- type
- RESULT
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-ba614565826895c77aa4
- requested nct id
- NCT00084747
- primary nct id
- NCT00084747
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- payload sha256
- 6bd1f73861e0de6a0d96114134e1c2450a6b1ff14cf59eea0ee8da372dae3c09
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-ba614565826895c77aa4
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT00084747
- occurrences
- context exact
- NCT00084747
- end
- 11
- exact text
- NCT00084747
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Plasma Cell Neoplasms
- query disease state id
- ds-plasma-cell-neoplasms
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- source json pointer
- /studies/842/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 69fb853a84f3e4a16e6a0004657e8c71b86d8d927a7292b29013c5633c99c8c1
Preserved source evidence · Not medical advice